Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.99
Oct 22 • 3:59 PM ET Dollar change+0.05 Percentage change(2.58%)
Aftermarket Close
2.00
Aftermarket • 7:30 PM ET Dollar change+0.01 Percentage change(0.50%)
Index
-
Market Cap
66.37M
Enterprise Value
-34.94M
Income
103.37M
Sales
68.47M
Book/sh
4.93
Cash/sh
5.89
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
78
IPO
Nov 17, 2011
P/E
0.75
Forward P/E
-
PEG
-
P/S
0.97
P/B
0.40
P/C
0.34
P/FCF
0.55
EV/EBITDA
-
EV/Sales
-0.51
Quick Ratio
3.83
Current Ratio
3.96
Debt/Eq
0.32
LT Debt/Eq
0.28
Option/Short
Yes / Yes
EPS (ttm)
2.66
EPS next Y
-1.00
EPS next Q
-0.27
EPS this Y
3742.86%
EPS next Y
-139.22%
EPS next 5Y
-
EPS past 3/5Y
83.35% 62.98%
Sales past 3/5Y
-5.83% 6.77%
EPS Y/Y TTM
401.39%
Sales Y/Y TTM
15.46%
EPS Q/Q
-117.40%
Sales Q/Q
14.04%
Insider Own
30.90%
Insider Trans
0.00%
Inst Own
22.65%
Inst Trans
2.99%
ROA
46.92%
ROE
107.48%
ROIC
53.19%
Gross Margin
58.88%
Oper. Margin
-42.86%
Profit Margin
150.97%
SMA20
-2.39%
SMA50
-17.79%
SMA200
-30.22%
Trades
Shs Outstand
33.31M
Shs Float
23.04M
52W High
4.53 -56.07%
52W Low
1.83 8.74%
Volatility
3.68% 4.02%
ATR (14)
0.09
RSI (14)
37.70
Beta
1.26
Rel Volume
0.42
Avg Volume
436.96K
Volume
183,355
Perf Week
4.19%
Perf Month
-14.96%
Perf Quarter
-40.42%
Perf Half Y
-10.76%
Perf YTD
-45.63%
Perf Year
-21.65%
Perf 3Y
6.99%
Perf 5Y
-95.58%
Perf 10Y
-94.96%
Prev Close
1.94
Price
1.99
Change %
2.58%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Resumed ROTH MKM Buy $10
Aug-04-22Initiated Ladenburg Thalmann Buy $6
Oct-02-20Initiated The Benchmark Company Buy $9
Dec-18-19Initiated B. Riley FBR Buy $9
Feb-28-18Initiated B. Riley FBR, Inc. Buy $10
Jul-11-17Initiated Rodman & Renshaw Buy $11
Mar-22-17Initiated JMP Securities Mkt Outperform
Oct-03-16Initiated ROTH Capital Buy $9
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Executive ChairmanDr. Lindsay Allan Rosenwald M.D.
CFO & Head of Corporate DevelopmentMr. David Jin
Chief Strategy OfficerDr. Xiaoqin Lu M.D.
J.D.Mr. Michael S. Weiss Esq.